Evaluation of factors affecting the duration of disease-modifying anti-rheumatic drugs application in patients with enthesitis-related arthritis

PAÇ KISAARSLAN A., SÖZERİ B., Gündüz Z., ZARARSIZ G., POYRAZOĞLU M. H., DÜŞÜNSEL R.

EUROPEAN JOURNAL OF RHEUMATOLOGY, cilt.6, sa.3, ss.130-135, 2019 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 6 Sayı: 3
  • Basım Tarihi: 2019
  • Doi Numarası: 10.5152/eurjrheum.2019.18180
  • Dergi Adı: EUROPEAN JOURNAL OF RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.130-135
  • Anahtar Kelimeler: Enthesitis-related arthritis, biological treatments, time, JUVENILE IDIOPATHIC ARTHRITIS, RHEUMATIC-DISEASES, SPONDYLOARTHRITIS, POPULATION, PREVALENCE, VALIDATION, CHILDREN, AGENTS
  • Erciyes Üniversitesi Adresli: Evet

Özet

Objective: Treatments for enthesitis-related arthritis (ERA) consist of a mono-or combination therapy with non-steroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs (DMARDs), and biological agents, and they are primarily based on adult studies and studies on other forms of juvenile idiopathic arthritis, depending on whether there is axial or peripheral involvement. We use DMARDs frequently in our daily practice, even in patients with axial involvement. The main reason for this is that the health insurance system in Turkey does not allow the use of Tumor Negrosis Factor (TNF) blockers as the first line of treatment. The aim of this study is to evaluate the factors affecting the duration of DMARDs application in patients with ERA.